




PHARMACEUTICAL 2023

Axsome Therapeutics Inc.
Rank 300 of 446





PHARMACEUTICAL 2023

Axsome Therapeutics Inc.
Rank 300 of 446

The relative strengths and weaknesses of Axsome Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Axsome Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Axsome Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.47%, being 43% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	245,641
Cost of Goods Sold	0
Intangible Assets	69,971
Liabilities, Current	96,561
Liabilities, Non-Current	94,259
Other Assets	15,141
Other Compr. Net Income	0
Other Expenses	12,635
Other Liabilities	31,100
Other Net Income	-7,335
Other Revenues	50,037
Property and Equipment	723
Research and Development	57,947
Selling, General and Administrative Expense	159,254

Output Variable	Value in 1000 USD
Assets	331,476
Liabilities	221,920
Expenses	229,836
Revenues	50,037
Stockholders Equity	109,556
Net Income	-187,134
Comprehensive Net Income	-187,134
Economic Capital Ratio	0.47%